Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...

Researchers with the Chinese Academy of Sciences have figured out why beer tastes better cold. It's all about ethanol, the ...

Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $64.12 which represents a slight increase of $5.74 or 9.83% from the prior close of $58.38. The stock opened at $58.46 and ...

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

The Battle Brewing Over Blood Tests for Cancer Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly challenge his rival to a ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...

Researchers investigated the relationship between the degree of food processing and type 2 diabetes risk, including which ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results ...